Skip to main content
Premium Trial:

Request an Annual Quote

Quidel's Q2 Revenues Fall 4 Percent

NEW YORK (GenomeWeb News) – Quidel reported after the close of the market Tuesday that its second-quarter revenues declined 4 percent year over year, due primarily to lower sales of its infectious disease diagnostic products.

The San Diego, Calif.-based diagnostics firm brought in total revenues of $29.7 million for the three months ended June 30, compared to $30.9 million for the second quarter of 2012. Analysts, on average had expected revenues of $33.2 million.

"Revenues in the second quarter were relatively flat year-over-year," Quidel President and CEO Douglas Bryant said in a statement. "Gains in new product sales were offset by a lower prevalence of Group A Strep than we saw last April, and the timing of shipments to our US distribution partners."

However, Bryant added that the firm is "seeing good traction on our recent commercial launch of AmpliVue, our handheld molecular product, and anticipate that our Sofia Group A Strep assay will be the next catalyst to drive Sofia placements in the near term."

Quidel posted a net loss of $1.8 million, or $.05 per share, for the quarter, compared to a profit of $3.1 million, or $.09 per share, for the second quarter of 2012. On an adjusted basis, its loss was $1.9 million, or $.06 per share, beating analysts' consensus estimate of $.11 per share.

The firm's R&D spending increased 16 percent to $7.9 million from $6.8 million, while its SG&A expenses climbed 3 percent to $13.2 million from $12.8 million.

Quidel finished the quarter with $22.8 million in cash and cash equivalents.

In Wednesday morning trade on the Nasdaq, shares of Quidel were down 3 percent at $27.26.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.